Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Unknown 25Completed 14Recruiting 13Not yet recruiting 12Active not recruiting 4Terminated 3

Sponsor Class

OTHER 4

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Gastrointestinal 3Gynecologic 1

Conditions

Pancreatic Neoplasms 2Ovarian Neoplasms 1Cholangiocarcinoma 1

Interventions

pembrolizumab 436Carboplatin 321Nivolumab 287Cyclophosphamide 280Specimen Handling 257Cisplatin 251Paclitaxel 248Magnetic Resonance Spectroscopy 248Radiotherapy 217Gemcitabine 180Dexamethasone 180Biopsy 177durvalumab 166atezolizumab 148Rituximab 138Lenalidomide 134Doxorubicin 134Docetaxel 130Bevacizumab 129Ipilimumab 125Radiation 118Capecitabine 117Pemetrexed 112Oxaliplatin 112Etoposide 111Radiosurgery 108Fluorouracil 108venetoclax 106fludarabine 106Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × surufatinib × Clear all
NCT05908747 2026-02-10

Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Active not recruiting
29 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT05481476 2025-09-04

Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer

Sun Yat-sen University

Phase 2 Active not recruiting
32 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT05652283 2024-11-27

Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

Anhui Provincial Cancer Hospital

Phase 2 Active not recruiting
37 enrolled
Gynecologic

Ovarian Neoplasms

NCT06239532 2024-11-21

HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma

Qilu Hospital of Shandong University

Phase 2 Active not recruiting
28 enrolled
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡